American journal of translational research · 2025
Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Min, Liang Chong, Feng Wei, Qin Jinbiao, Zhao Wuwei
Аннотация
OBJECTIVE: To evaluate the therapeutic effectiveness of donepezil hydrochloride in patients with Parkinson's disease (PD) and inform subsequent management strategies.
METHODS: We systematically reviewed randomized and non-randomized studies on donepezil hydrochloride in PD patients, retrieved from PubMed, Web of Science, Embase, and the Cochrane Library, covering data from inception to March 2025. Meta-analysis was performed using RevMan 5.4 software.
RESULTS: Ten eligible studies were included. The meta-analysis revealed significant improvements in Mini-Mental State Examination (MMSE) scores in the treatment group compared to controls (SMD = 1.67, 95% CI [0.81, 2.54], P < 0.0001). The Unified Parkinson's Disease Rating Scale (UPDRS) scores were significantly reduced (SMD = -2.79, 95% CI: -4.85 to -0.74, P = 0.008), as were Clinician's Interview-Based Impression of Change (CIBIC+) scores (SMD = -0.27, 95% CI: -0.45 to -0.08, P = 0.004). Subgroup analysis indicated consistent improvements in MMSE scores across different subgroups, with significant differences observed. Heterogeneity was found in the age subgroup but not in the disease duration subgroup (< 3 years). Adverse events occurred in 42.07% (374/889) of the treatment group, with no heterogeneity across studies (I2 = 0%) and a statistically significant increase in risk (RR = 1.46, 95% CI [1.15, 1.84], P = 0.002).
CONCLUSION: The meta-analysis suggests that donepezil hydrochloride provides cognitive benefits for PD patients. However, the higher incidence of adverse reactions warrants careful consideration of the benefits and risks when using donepezil in clinical practice.
METHODS: We systematically reviewed randomized and non-randomized studies on donepezil hydrochloride in PD patients, retrieved from PubMed, Web of Science, Embase, and the Cochrane Library, covering data from inception to March 2025. Meta-analysis was performed using RevMan 5.4 software.
RESULTS: Ten eligible studies were included. The meta-analysis revealed significant improvements in Mini-Mental State Examination (MMSE) scores in the treatment group compared to controls (SMD = 1.67, 95% CI [0.81, 2.54], P < 0.0001). The Unified Parkinson's Disease Rating Scale (UPDRS) scores were significantly reduced (SMD = -2.79, 95% CI: -4.85 to -0.74, P = 0.008), as were Clinician's Interview-Based Impression of Change (CIBIC+) scores (SMD = -0.27, 95% CI: -0.45 to -0.08, P = 0.004). Subgroup analysis indicated consistent improvements in MMSE scores across different subgroups, with significant differences observed. Heterogeneity was found in the age subgroup but not in the disease duration subgroup (< 3 years). Adverse events occurred in 42.07% (374/889) of the treatment group, with no heterogeneity across studies (I2 = 0%) and a statistically significant increase in risk (RR = 1.46, 95% CI [1.15, 1.84], P = 0.002).
CONCLUSION: The meta-analysis suggests that donepezil hydrochloride provides cognitive benefits for PD patients. However, the higher incidence of adverse reactions warrants careful consideration of the benefits and risks when using donepezil in clinical practice.